SilverStream Medical News
5 articles๐ Singapore, We're Certified! ๐ SilverStream Solution Arrives!
We are thrilled to announce that SilverStream Solution is officially certified by Health Sciences Authority (HSA) Singapore! ๐
This milestone marks another step in expanding our global presence, bringing our innovative wound care solutions to more healthcare professionals and patients worldwide. ๐
We're excited to partner with MedAiD Solutions Pte Ltd, our partner, to ensure a successful launch in Singapore. Together, we're comm
growth-positive
Wound care co EnzySurge raises $4.1m
EnzySurge, a wound care treatment developer, has raised $11 million from private investors, including the present round. The companys valuation is $20 million. EnzySurge plans to use the investment to speed up penetration of the US market and expand marketing efforts to Europe. They have received an offer for an IPO on the Tel Aviv Stock Exchange but have not yet decided whether to go this route. EnzySurge recently obtained FDA approval for its SilverStream solution for wound management. The company aims to provide treatment for various types of wounds, including ulcers, burns, and cuts.
InvestmentPublic TradingExpand
growth-positive
ืืืจืช ืื ืืืกืจื' ืืืืกื 2.5 ืืืืืื ืืืืจ
Israeli life sciences company EnzySurge has raised $2.5 million in funding from private investors. The company has raised a total of $10 million to date. EnzySurge develops solutions for the treatment of chronic wounds. The wound care market is estimated to be worth $4 billion per year. Following FDA approval, EnzySurge can now sell its developed active healing solution without a prescription, opening up a new market for wound care products. The company plans to use the investment to continue its penetration into the American market. EnzySurge recently completed a successful clinical trial in several Israeli hospitals, showing improvement in healing chronic wounds and reducing healing time.
Investment
growth-positive
EnzySurge Raises US$2 Million Proceeds Will be Used to Accelerate Market Launch of its Wound Care Product in 2008 BioSpace
EnzySurge Ltd. expects to expand its recent $2 million private investment round to $3 million. The company plans to use the additional capital to accelerate the FDA approval process and expand its marketing efforts for its DermaStream product line, which offers innovative solutions for chronic wound management. EnzySurges technology allows for continuous streaming of therapeutic solutions throughout all phases of wound treatment. The company aims to launch its first product in the second half of 2008. Chronic wounds affect a significant portion of the population and current treatment options are expensive and only partially effective. EnzySurges solution aims to improve healing and reduce treatment costs. The company recently completed a clinical study demonstrating safety and accelerated wound closure with its enzymatic solution.
InvestmentExpand
growth-positive
Wound healing co EnzySurge raises $1.7m
Israeli start-up EnzySurge has closed its third financing round, raising $1.7 million from private investors at a value of $7 million. The company has developed treatments for chronic wounds and recently received FDA approval for its product named DermaStream. EnzySurge has also completed the development of a new solution-based treatment called EnzyStream, which is currently awaiting FDA approval. The market for treatments for chronic wounds is growing and EnzySurge is conducting safety and efficacy trials for its products.
Investment
